Breast cancer drug 'too expensive' for NHS

A drug that can extend the lives of some women with advanced breast cancer has been rejected for NHS use because it is too expensive.

Kadcyal can give patients with HER2-positive breast cancer which has spread to other parts of the body and where initial treatments have failed an additional six months of life.

The National Institute for Health and Care Excellence (Nice) said the drug was too expensive to recommend for widespread use in the health service.

View all 5 updates ›

Breast cancer drug decision 'an injustice'

The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.

Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."

Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.

Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.

– Dr Jayson Dallas

More top news